Oculis Holding AG (OCS) Surges 8.2%: Is This an Indication of Further Gains?

Oculis Holding AG (OCS) shares ended the last trading session 8.2% higher at $14.28. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 10.5% gain over the past four weeks. The company is developing OCS-01, a topical eye drop candidate for treating diabetic macular edema and inflammation and pain following cataract surgery, OCS-02 (licaminlimab), a topical biologic anti-TNFα eye drop candidate for dry eye disease and ...